ALT · Why this verdict
Why Altimmune (ALT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Altimmune's RSI-81 bounce looks like an overbought bear-market rally within a confirmed downtrend, compounded by extreme cash burn and justified 22% short interest, and the rejected, implausible analyst price target means headline upside figures should not be trusted here, even though the company has beaten earnings in 3 of its last 4 quarters.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
An RSI of 81 signals an overbought bounce within a still-confirmed downtrend, with the 30-day moving-average slope at -2.9%, a classic bear-rally pattern rather than a genuine reversal. Momentum breakdown | The moving-average slope should turn positive for the bounce to be considered a genuine trend reversal rather than a bear rally. | →Stable |
| CounterRising on-balance volume alongside the RSI spike could indicate real accumulation ahead of a durable reversal rather than a fleeting bounce. | ||
Free cash flow runs at roughly -118,061% of revenue, an extreme cash-burn rate typical of a pre-revenue clinical-stage biotech but a major quality red flag. Quality breakdown | The cash-burn rate should moderate substantially as clinical programs mature or revenue begins to scale. | →Stable |
| CounterA near-zero revenue base mechanically produces an extreme negative percentage even with a modest absolute cash-burn figure, so the metric may overstate the actual risk. | ||
The engine flags the stock's 22% short interest as justified by fundamentals rather than reflecting a squeeze opportunity. Risk breakdown | Short interest should decline from 22% if the fundamental picture improves. | →Stable |
| CounterA 22% short interest in a binary clinical-stage biotech can still trigger a sharp squeeze on unexpected positive trial data regardless of whether it is fundamentally justified. | ||
The raw analyst price target was rejected as implausible at 4.9 times the current price, so the engine fell back to a technical take-profit, meaning headline analyst-upside figures should not be trusted here. Bear case | A revised, credible analyst target should emerge to restore confidence in the analyst-upside signal. | →Stable |
| CounterThe stale target may simply not have been updated yet following a sharp price decline, rather than reflecting a genuinely broken valuation model. | ||
The company has beaten estimates in 3 of its last 4 quarters with a positive average surprise of 13.4%. Earnings | The beat rate should continue at the next report in 38 days for the execution thesis to hold. | →Stable |
| CounterClinical-stage biotech earnings beats are often driven by expense timing rather than commercial progress, limiting their predictive value. | ||
An RSI of 81 signals an overbought bounce within a still-confirmed downtrend, with the 30-day moving-average slope at -2.9%, a classic bear-rally pattern rather than a genuine reversal.
→StableMomentum breakdown
- Expectation
- The moving-average slope should turn positive for the bounce to be considered a genuine trend reversal rather than a bear rally.
CounterRising on-balance volume alongside the RSI spike could indicate real accumulation ahead of a durable reversal rather than a fleeting bounce.
Free cash flow runs at roughly -118,061% of revenue, an extreme cash-burn rate typical of a pre-revenue clinical-stage biotech but a major quality red flag.
→StableQuality breakdown
- Expectation
- The cash-burn rate should moderate substantially as clinical programs mature or revenue begins to scale.
CounterA near-zero revenue base mechanically produces an extreme negative percentage even with a modest absolute cash-burn figure, so the metric may overstate the actual risk.
The engine flags the stock's 22% short interest as justified by fundamentals rather than reflecting a squeeze opportunity.
→StableRisk breakdown
- Expectation
- Short interest should decline from 22% if the fundamental picture improves.
CounterA 22% short interest in a binary clinical-stage biotech can still trigger a sharp squeeze on unexpected positive trial data regardless of whether it is fundamentally justified.
The raw analyst price target was rejected as implausible at 4.9 times the current price, so the engine fell back to a technical take-profit, meaning headline analyst-upside figures should not be trusted here.
→StableBear case
- Expectation
- A revised, credible analyst target should emerge to restore confidence in the analyst-upside signal.
CounterThe stale target may simply not have been updated yet following a sharp price decline, rather than reflecting a genuinely broken valuation model.
The company has beaten estimates in 3 of its last 4 quarters with a positive average surprise of 13.4%.
→StableEarnings
- Expectation
- The beat rate should continue at the next report in 38 days for the execution thesis to hold.
CounterClinical-stage biotech earnings beats are often driven by expense timing rather than commercial progress, limiting their predictive value.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -157375% of revenue
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 3.7 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 4.1 |
- ▸Capitulation risk (RSI 23, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -8.1%/30d — confirmed downtrend
Sentiment
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 5.0 |
| Price target | 10.0 |
- ▸Analyst upside: 715%
Insider
7.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.5 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider buying (low materiality) — $44,250 (0.011% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.2 |
| growth rank | 5.0 |
Technical
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.9 |
| support resistance | 8.8 |
| 52w position | 0.0 |
Risk (lower is worse)
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.3 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 8.8 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 9.7 |
- ▸High short interest justified: 22%
- ▸High IV: 199%
Catalyst
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 7.7 |
| news activity | 5.0 |
- ▸Earnings in 6 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (4)
- INSIDER:OK
- 8K:CLEAN
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:2.6<4.5
- DEATH_CROSS:HARD_BLOCK
- EARNINGS_PROXIMITY:6d<=7d
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
11.3%
Sizing output
AVOID
SetupFalling Knife — Death cross, below all MAs, RSI 23, MACD bearish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -67% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.6<4.5 outcome against Insider at 7.5 and asymmetric R:R of 0.00.
The strongest dimensions are Insider at 7.5, Sentiment at 7.0, and Catalyst at 5.7; the weakest are Quality at 1.8, Momentum at 2.6, and Risk (lower is worse) at 4.3. The V9 engine flagged 3 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Overbought Bear Rally Momentum
Trip if30-day moving-average slope rises above 0%, ending the confirmed downtrend.
- P2Extreme Cash Burn
Trip ifFree cash flow rises above -1000% of revenue from the current -118,061%.
- P3Justified Elevated Short Interest
Trip ifShort interest falls below 12% from the current 22%.
- P4Rejected Implausible Analyst Target
Trip ifA revised analyst target is published at less than 2x the current price.
- P5Earnings Beat History
Trip ifAverage earnings surprise falls below 0% from the current 13.4%.